Healthcare Sector Review: 3SBio Operations, Delcath Systems

3SBio Inc. (NASDAQ:SSRX): The company’s 2012 operating objectives include: Explore the potential market in the renal care area to further strengthen our leadership position in the nephrology area. Evaluate manufacturing options for small-molecule medicines. Initiate Phase I trial of NuPiao, our next-generation EPO product. Initiate a registration trial of Feraheme, an IV iron supplement. Continue to explore global biosimilar opportunities and initiate the approval process in selected markets. Work with Isotechnika on initiating a global. Phase III multi-center trial of voclosporin for the prevention of kidney transplant rejection. Prepare application to conduct clinical trials in China for pegsiticase (Uricase-PEG 20), a treatment for refractory gout, and identify potential partners for development outside China. Strengthen existing strategic partnerships while continuing to seek opportunities that leverage our balance sheet, strong nephrology and oncology franchises and recent additions to our product pipeline.

The shares closed at $14.19, up $2.19, or 18.25%, on the day. Its market capitalization is $311.20 million.

Delcath Systems, Inc. (NASDAQ:DCTH): Delcath Systems announced that Quintiles will provide a specialized team of Medical Science Liaisons, or MSLs, to support the launch of the Hepatic CHEMOSAT Delivery system for the treatment of cancers in the liver in France, Germany, Italy, Netherlands, Spain, Ireland and the U.K.. In addition, it will provide medical communication to support patient advocacy, key opinion leader development, and field force materials.

The shares closed at $3.49, down $0.36, or 9.35%, on the day. Its market capitalization is $168.23 million.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Stella Mariz at

To contact the editor responsible for this story: Damien Hoffman at